Skip to main
BCAX

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics Inc is positioned favorably due to its innovative bifunctional therapy, ficera, which is demonstrating potential in addressing solid tumors with a robust clinical profile. The ongoing advancements in dosing and efficacy suggest a strong possibility of achieving regulatory approval and capturing a significant share of the head and neck squamous cell carcinoma (HNSCC) market, potentially reaching up to 30%. Additionally, the promising data observed in treating various patient populations, alongside confidence in overcoming standard of care in certain indications, underpins the positive outlook for the company’s stock.

Bears say

Bicara Therapeutics Inc. faces a negative outlook due to potential underperformance of its lead candidate, ficera, indicating a reduced probability of success in treating head and neck squamous cell carcinoma (HNSCC) at only 30%. The clinical landscape shows that five-year survival rates for metastatic cases drastically decrease to around 15%, while the lack of differentiated clinical data may hinder ficera's market competitiveness. Furthermore, the anticipated decline in HPV-attributable HNSCC incidences due to increased vaccination rates could further threaten the company's sales potential in a challenging therapeutic environment.

BCAX has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 7 analysts, BCAX has a Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.